Carmelo Gurnari

List of Publications by Year
in descending order

90 papers	747 citations	686830 13 h-index	676716 22 g-index
92 all docs	92 docs citations	92 times ranked	769 citing authors

#	Article	IF	Citations
1	Tâ€cell large granular lymphocytic leukemia associated with inclusion body myositis. International Journal of Laboratory Hematology, 2022, 44, 27-28.	0.7	2
2	â€˜We cannot paint them all with the same brushâ€™: the need for a better definition of patients with myelodysplastic syndromes for clinical trial design. British Journal of Haematology, 2022, 196, 268-269.	1.2	4
3	TET2 mutations as a part of DNA dioxygenase deficiency in myelodysplastic syndromes. Blood Advances, 2022, 6, 100-107.	2.5	12
4	Recruitment of MLL1 complex is essential for SETBP1 to induce myeloid transformation. IScience, 2022, 25, 103679.	1.9	6
5	A study of Telomerase Reverse Transcriptase rare variants in myeloid neoplasia. Hematological Oncology, 2022, , .	0.8	3
6	Circulating microbial content in myeloid malignancy patients is associated with disease subtypes and patient outcomes. Nature Communications, 2022, 13, 1038.	5.8	13
7	Personalized Risk Schemes and Machine Learning to Empower Genomic Prognostication Models in Myelodysplastic Syndromes. International Journal of Molecular Sciences, 2022, 23, 2802.	1.8	10
8	Aplastic anemia: Quo vadis?. Seminars in Hematology, 2022, 59, 54-55.	1.8	3
9	Single-cell characterization of leukemic and non-leukemic immune repertoires in CD8+ T-cell large granular lymphocytic leukemia. Nature Communications, 2022, 13, 1981.	5.8	23
10	Demethylation and Up-Regulation of an Oncogene after Hypomethylating Therapy. New England Journal of Medicine, 2022, 386, 1998-2010.	13.9	25
11	Rare germline alterations of myeloperoxidase predispose to myeloid neoplasms. Leukemia, 2022, 36, 2086-2096.	3.3	2
12	Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinicoâ€biological parameters. British Journal of Haematology, 2021, 193, 129-132.	1.2	17
13	Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria. Blood Cells, Molecules, and Diseases, 2021, 87, 102528.	0.6	8
14	Novel invariant features of Good syndrome. Leukemia, 2021, 35, 1792-1796.	3.3	11
15	Molecular Targeted Therapy in Myelodysplastic Syndromes: New Options for Tailored Treatments. Cancers, 2021, 13, 784.	1.7	14
16	From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms: The Silent Way of Cancer Progression. Biology, 2021, 10, 128.	1.3	5
17	Clonal trajectories and cellular dynamics of myeloid neoplasms with SF3B1 mutations. Leukemia, 2021, 35, 3324-3328.	3.3	2
18	Vacuolization of hematopoietic precursors: an enigma with multiple etiologies. Blood, 2021, 137, 3685-3689.	0.6	50

#	Article	IF	Citations
19	The Interactome between Metabolism and Gene Mutations in Myeloid Malignancies. International Journal of Molecular Sciences, 2021, 22, 3135.	1.8	5
20	How I manage acquired pure red cell aplasia in adults. Blood, 2021, 137, 2001-2009.	0.6	29
21	Myeloid lncRNA LOUP mediates opposing regulatory effects of RUNX1 and RUNX1-ETO in t(8;21) AML. Blood, 2021, 138, 1331-1344.	0.6	19
22	Friend or foe? The case of Wilms' Tumor 1 (WT1) mutations in acute myeloid leukemia. Blood Cells, Molecules, and Diseases, 2021, 88, 102549.	0.6	1
23	Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia. Blood, 2021, 138, 1885-1895.	0.6	32
24	Clinical and basic implications of dynamic T cell receptor clonotyping in hematopoietic cell transplantation. JCI Insight, 2021, 6, .	2.3	12
25	A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics. Cells, 2021, 10, 1961.	1.8	16
26	Copper Deficiency. New England Journal of Medicine, 2021, 385, 640-640.	13.9	5
27	Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols. Acta OncolÃ³gica, 2021, 60, 1520-1526.	0.8	2
28	Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia. Cell Stem Cell, 2021, 28, 1966-1981.e6.	5.2	49
29	Chronic Buddâ€“Chiari syndrome in paroxysmal nocturnal haemoglobinuria. Lancet, The, 2021, 398, e14.	6.3	2
30	Large Granular Lymphocytic Leukemia: From Immunopathogenesis to Treatment of Refractory Disease. Cancers, 2021, 13, 4418.	1.7	11
31	Monoclonal IgM gammopathy in adult acquired pure red cell aplasia: culprit or innocent bystander?. Blood Cells, Molecules, and Diseases, 2021, 91, 102595.	0.6	2
32	Acute Promyelocytic Leukemia in Children: A Model of Precision Medicine and Chemotherapy-Free Therapy. International Journal of Molecular Sciences, 2021, 22, 642.	1.8	12
33	Implication of PIGA genotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria. Leukemia, 2021, 35, 2431-2434.	3.3	10
34	Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants. Blood Cancer Journal, 2021, 11, 167.	2.8	11
35	The similarity of class II HLA genotypes defines patterns of autoreactivity in idiopathic bone marrow failure disorders. Blood, 2021, 138, 2781-2798.	0.6	27
36	Immunogenetic, Molecular and Clinical Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. Blood, 2021, 138, 602-602.	0.6	1

#	Article	IF	Citations
37	A Novel Machine Learning-Derived Molecular Classification Scheme with Prognostic Significance. Blood, 2021, 138, 3666-3666.	0.6	1
38	What are the considerations for the pharmacotherapeutic management of acute promyelocytic leukemia in children?. Expert Opinion on Pharmacotherapy, 2021, , 1-6.	0.9	0
39	Is nature truly healing itself? Spontaneous remissions in Paroxysmal Nocturnal Hemoglobinuria. Blood Cancer Journal, 2021, 11, 187.	2.8	11
40	Is Nature Truly Healing Itself? Spontaneous Remissions and Clonal Replacement in Paroxysmal Nocturnal Hemoglobinuria. Blood, 2021, 138, 4303-4303.	0.6	0
41	Molecular characterization of the histone acetyltransferase CREBBP/EP300 genes in myeloid neoplasia. Leukemia, 2021, , .	3.3	1
42	Mutant TP53 prevents Telomere Shortening in Acute Myeloid Leukemia. Blood, 2021, 138, 375-375.	0.6	2
43	Spectrum of Molecular Modes of Immune Escape in Idiopathic Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. Blood, 2021, 138, 603-603.	0.6	1
44	TERT Rare Variants in Myeloid Neoplasia: Lack of Clinical Impact or Role as Risk Alleles. Blood, 2021, 138, 1537-1537.	0.6	1
45	Molecular Signatures of Immune Pressure and Immune Escape in Hematological Malignancies. Blood, 2021, 138, 1093-1093.	0.6	0
46	Transcriptomic Profile Identifies Early Signatures of Immunoediting and a Potential Role for VISTA As a Molecular Target in Acute Myeloid Leukemia. Blood, 2021, 138, 4467-4467.	0.6	1
47	Have we reached a molecular era in myelodysplastic syndromes?. Hematology American Society of Hematology Education Program, 2021, 2021, 418-427.	0.9	23
48	Current Opinions on the Clinical Utility of Ravulizumab for the Treatment of Paroxysmal Nocturnal Hemoglobinuria. Therapeutics and Clinical Risk Management, 2021, Volume 17, 1343-1351.	0.9	2
49	Alternative Splicing in Myeloid Malignancies. Biomedicines, 2021, 9, 1844.	1.4	5
50	WT1 evaluation in higher-risk myelodysplastic syndrome patients treated with azacitidine. Leukemia and Lymphoma, 2020, 61, 979-982.	0.6	1
51	Terminal deoxynucleotidyl transferase (TdT) expression is associated with FLT3-ITD mutations in Acute Myeloid Leukemia. Leukemia Research, 2020, 99, 106462.	0.4	4
52	Deciphering the Therapeutic Resistance in Acute Myeloid Leukemia. International Journal of Molecular Sciences, 2020, 21, 8505.	1.8	12
53	Essential Thrombocythemia and Acquired von Willebrand Syndrome: The Shadowlands between Thrombosis and Bleeding. Cancers, 2020, 12, 1746.	1.7	18
54	From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia. Cancers, 2020, 12, 357.	1.7	11

#	Article	IF	Citations
55	The Clonal Trajectories of SF3B1 Mutations in Myeloid Neoplasia. Blood, 2020, 136, 8-8.	0.6	1
56	The Genomic Landscape of Myeloid Neoplasms Evolved from AA/PNH. Blood, 2020, 136, 2-2.	0.6	1
57	Impact of Pathogenic Germ Line Variants in Adults with Acquired Bone Marrow Failure Syndromes Vs. Myeloid Neoplasia. Blood, 2020, 136, 1-1.	0.6	1
58	Early detection of IgH monoclonal rearrangement in follicular spicules of the nose preceding multiple myeloma diagnosis. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 364-366.	0.8	0
59	Leveraging Whole Genome Sequencing to Define the Mutational Landscape in Paroxysmal Nocturnal Hemoglobinuria. Blood, 2020, 136, 8-8.	0.6	0
60	Type of TP53 Mutations Affects Subclonal Configuration and Selection Pressure for Acquisition of Additional Hits in Contralateral Alleles. Blood, 2020, 136, 25-25.	0.6	0
61	Immunogenomics of Paroxysmal Nocturnal Hemoglobinuria: A Model of Immune Escape. Blood, 2020, 136, 21-22.	0.6	0
62	Impact of HLA Evolutionary Divergence on Clinical Features of Patients with Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria. Blood, 2020, 136, 2-3.	0.6	0
63	Inhibition of Critical DNA Dioxygenase Activity in IDH1/2 Mutant Myeloid Neoplasms. Blood, 2020, 136, 28-28.	0.6	0
64	The Genomic Landscape of Wilms' Tumor 1 (WT1) Mutant Acute Myeloid Leukemia. Blood, 2020, 136, 28-28.	0.6	1
65	Implication of Piga Genotype on Clinical Features of PNH. Blood, 2020, 136, 34-35.	0.6	0
66	Double Genetic Hits and Subclonal Mosaicism in the Ras Signaling Pathway in Myeloid Neoplasia. Blood, 2020, 136, 34-35.	0.6	0
67	Immunogenomics of Aplastic Anemia: The Role of HLA Somatic Mutations and the HLA Evolutionary Divergence. Blood, 2020, 136, 20-21.	0.6	0
68	Rare Germline Alterations of Myeloperoxidase Predispose to Myeloid Neoplasms and Are Associated with Increased Circulating Burden of Microbial DNA. Blood, 2020, 136, 2-3.	0.6	0
69	Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: From Recapitulation/Acquisition of Leukemogenic Hits to Immune Escape Due to Somatic Class I/ II HLA Mutations. Blood, 2020, 136, 21-21.	0.6	0
70	Comparative Genomic Analysis of Adolescents and Young Adults Versus Elderly with Acute Myeloid Leukemia. Blood, 2020, 136, 18-18.	0.6	0
71	Arsenic trioxide and allâ€trans retinoic acid treatment for childhood acute promyelocytic leukaemia. British Journal of Haematology, 2019, 185, 360-363.	1.2	14
72	Applications and efficiency of flow cytometry for leukemia diagnostics. Expert Review of Molecular Diagnostics, 2019, 19, 1089-1097.	1.5	14

#	Article	IF	Citations
73	Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome. Leukemia Research, 2019, 84, 106191.	0.4	5
74	The Role of Forkhead Box Proteins in Acute Myeloid Leukemia. Cancers, 2019, 11, 865.	1.7	22
75	Genetic analysis of erythrocytosis reveals possible causative and modifier gene mutations. British Journal of Haematology, 2019, 186, e100-e103.	1.2	2
76	When Poisons Cure: The Case of Arsenic in Acute Promyelocytic Leukemia. Chemotherapy, 2019, 64, 238-247.	0.8	19
77	STAT5b-RARa-positive acute myeloid leukemia: Diagnostic and therapeutic challenges of a rare AML subtype. Leukemia Research, 2019, 78, 21-23.	0.4	8
78	The emerging role of measurable residual disease detection in AML in morphologic remission. Seminars in Hematology, 2019, 56, 125-130.	1.8	25
79	Early Intracranial Hemorrhages in Acute Promyelocytic Leukemia: Analysis of Neuroradiological and Clinico-Biological Parameters. Blood, 2019, 134, 5170-5170.	0.6	0
80	Validation of SIE, Sies, GITMO Operational Criteria for the Definition of Fitness in Elderly Patients Affected with Acute Myeloid Leukemia: A Six-Years Retrospective Real-Life Experience. Blood, 2019, 134, 2150-2150.	0.6	2
81	Acute Promyelocytic Leukemia (APL) in Very Elderly Patients: Real-Life behind Protocols. Blood, 2019, 134, 3845-3845.	0.6	1
82	Mutational Profile of Leukemic Stem Cells in FLT3-ITD Mutated AML. Blood, 2019, 134, 1458-1458.	0.6	1
83	Recurrent Sweet's syndrome in a patient with multiple myeloma. Clinical Case Reports (discontinued), 2018, 6, 1958-1960.	0.2	1
84	Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes. Leukemia Research, 2018, 71, 89-91.	0.4	2
85	Congenital Rhabdomyosarcoma: a different clinical presentation in two cases. BMC Pediatrics, 2018, 18, 166.	0.7	12
86	Unravelling Genetic Mechanisms of Erythrocytosis: A Real-Life Experience from a Single Center. Blood, 2018, 132, 3617-3617.	0.6	0
87	The combination of bortezomib with chemotherapy to treatÂrelapsed/refractory acute lymphoblastic leukaemia of childhood. British Journal of Haematology, 2017, 176, 629-636.	1.2	56
88	Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia. Molecular and Clinical Oncology, 2017, 8, 463-465.	0.4	4
89	Clinical Outcome and Immune Recovery after Adoptive Infusion of BPX-501 Cells (donor) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5 Depleted HLA-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT). Biology of Blood and Marrow Transplantation, 2016, 22, S139.	2.0	0
90	Vitamin C Deficiency in Patients With Acute Myeloid Leukemia. Frontiers in Oncology, 0, 12, .	1.3	4